Millennium Shops Atherosclerosis Candidate After Positive Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma seeks a partner before bringing the CCR2 antagonist into Phase III, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Millennium/Sanofi Discontinue Phase II CCR1 Inhibitor For Rheumatoid Arthritis
Candidate demonstrated safety but did not reach prespecified endpoint, Millennium CEO Dunsire says.
Millennium/Sanofi Discontinue Phase II CCR1 Inhibitor For Rheumatoid Arthritis
Candidate demonstrated safety but did not reach prespecified endpoint, Millennium CEO Dunsire says.
Millennium Chief Medical Officer Nancy Simonian: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses Millennium’s key pipeline projects, including the T cell integrin antibody MLN0002 for inflammatory bowel disease.